Left ventricular assist device implantation successfully improved cardiac function from NYHA class IV to I-II and increased left ventricular ejection fraction from 17% to 48% in a patient with acromegaly-induced end-stage heart failure.
Case Report (n=1)
No
Does LVAD implantation improve symptoms and stabilize heart condition in a patient with end-stage heart failure due to acromegalic cardiomyopathy?
LVAD implantation may be a viable and effective therapeutic option for managing end-stage heart failure secondary to acromegalic cardiomyopathy.
Acromegaly-related heart failure, as a rare cause of heart failure, presents a substantial healthcare challenge owing to their insidious onset and overlapping symptoms. Current management often includes systemic anti-heart failure treatment and reducing growth hormone(GH) levels, yet cardiac outcomes remain unideal. Left ventricular assist device(LVAD) may be a valuable therapeutic option in such patients. We report a case of a 54-year-old Chinese female diagnosed with severe congestive heart failure, classified as New York Heart Association class IV. The clinical symptom failed to improve, despite systemic anti-heart failure treatment. Heart failure arising from acromegaly was suspected due to her facial features, and confirmed through elevated levels of GH and a pituitary macroadenoma demonstrated by magnetic resonance imaging. Upon diagnosis of acromegaly, bromocriptine was initiated to reduce GH levels. Subsequently, our multidisciplinary team administered LVAD implantation, resulted in cardiac symptoms completely relieved within one week postoperatively. During one-year follow-up, the patient's heart condition remained stable and the GH gradually decreased. LVAD may be a valuable therapeutic option in acromegaly-related heart failure patients.
Guo et al. (Thu,) conducted a case report in Acromegalic cardiomyopathy with end-stage heart failure (n=1). Left ventricular assist device (LVAD) was evaluated on Cardiac function and symptom improvement. Left ventricular assist device implantation successfully improved cardiac function from NYHA class IV to I-II and increased left ventricular ejection fraction from 17% to 48% in a patient with acromegaly-induced end-stage heart failure.